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Abstract
Background: Body mass index (BMI, kg/m2) may not be the best marker for estimating the risk
of obesity-related disease. Consistent with physiologic observations, an alternative index uses waist
circumference (WC) and fasting triglycerides (TG) concentration to describe lipid
overaccumulation.
Methods: The WC (estimated population minimum 65 cm for men and 58 cm for women) and
TG concentration from the third National Health and Nutrition Examination Survey (N = 9,180,
statistically weighted to represent 100.05 million US adults) were used to compute a "lipid
accumulation product" [LAP = (WC-65) × TG for men and (WC-58) × TG for women] and to
describe the population distribution of LAP. LAP and BMI were compared as categorical variables
and as log-transformed continuous variables for their ability to identify adverse levels of 11
cardiovascular risk factors.
Results: Nearly half of the represented population was discordant for their quartile assignments
to LAP and BMI. When 23.54 million with ordinal LAP quartile > BMI quartile were compared with
25.36 million with ordinal BMI quartile > LAP quartile (regression models adjusted for race-
ethnicity and sex) the former had more adverse risk levels than the latter (p < 0.002) for seven lipid
variables, uric acid concentration, heart rate, systolic and diastolic blood pressure. Further
adjustment for age did not materially alter these comparisons except for blood pressures (p > 0.1).
As continuous variables, LAP provided a consistently more adverse beta coefficient (slope) than
BMI for nine cardiovascular risk variables (p < 0.01), but not for blood pressures (p > 0.2).
Conclusion: LAP (describing lipid overaccumulation) performed better than BMI (describing
weight overaccumulation) for identifying US adults at cardiovascular risk. Compared to BMI, LAP
might better predict the incidence of cardiovascular disease, but this hypothesis needs prospective
testing.
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Background
Obesity is commonly understood to imply excess fat, but
it is ordinarily classified according to excess weight. This
semantic inconsistency may help to explain why the body
mass index (BMI, kg/m2) – a popular marker for relative
weight – performs only modestly as a predictor of medical
risk [1]. Researchers have increasingly appreciated that
adipose tissue has complex functions [2,3], and that these
functions may vary according to anatomic region [4-8].
Some of the region-specific functions of adipose tissue are
beneficial, such as storing and buffering daily fluxes of cir-
culating lipid fuels [9]. Thus, one cannot assume that a
high relative weight or global adiposity is always
deleterious.
In the current era of increasing obesity, we should attempt
to define and measure lipid accumulation specifically in
those contexts where accumulation may represent a phys-
iologic danger [10,11]. These contexts might be described
as lipid overaccumulation [12]. At the same time we
should avoid attributing culpability to components of
adipose or lean tissue that are enlarged but might enhance
physiologic processes or reduce the risk of disease.
This paper first describes a simple index for estimating
lipid overaccumulation among adults. Next, to demon-
strate the utility of the lipid overaccumulation concept,
this paper tests the hypothesis that the described index is
better correlated than BMI with a variety of cardiovascular
risk factors. This hypothesis should not be surprising since
the BMI can neither distinguish between fat and lean tis-
sues nor identify the anatomic location or function of dis-
tinct fat depots.
The proposed index – designated the "lipid accumulation
product" (LAP) – is based on a combination of two meas-
urements that are safe and inexpensive to obtain. One is
waist circumference (WC), a measure of truncal fat that
includes the visceral (intra-abdominal) depot. The other
is the fasting concentration of circulating triglycerides
(TG), the esterified, long-chain fatty acids that circulate
through blood contained stably inside lipoproteins. Both
waist size and TG concentration tend to rise with age
[13,14], suggesting that their values are subject to accu-
mulation over time. Waist size and circulating TGs are
each continuously associated with metabolic insulin
resistance [15,16], daylong triglyceridemia [17], and car-
diovascular risk [18-20].
Although previous papers have proposed that the combi-
nation of enlarged waist and elevated TGs might serve as
a dichotomous risk marker [21,22], the simple index
described here was developed to express a continuous risk
function. If LAP is better correlated than BMI with cardio-
vascular risk factors, this finding would support the
notion that the overaccumulation of lipid carries worse
cardiovascular consequences than the less specific overac-
cumulation of weight.
Methods
Defining the lipid accumulation product (LAP)
Data were obtained from the third National Health and
Nutrition Examination Survey (NHANES III), a probabil-
ity sample of the US civilian, noninstitutionalized popu-
lation that included an oversample of non-Hispanic
blacks and Mexican Americans [23]. NHANES III, con-
ducted over the period 1988–1994, was unique among
large US surveys because it incorporated assays of serum
apolipoproteins B and A1 (ApoB, ApoA1; restricted to sur-
vey years 1988–1991). The analytic population from the
seven-year survey contained 4,447 male and 4,733 female
participants who were aged 18+ years, not pregnant, had
fasted 8–19 hours before their laboratory examination,
and had data available on basic anthropometry and fast-
ing serum TGs (excluding three persons with a TG concen-
tration >15 mmol/L). Participants were asked to complete
a household interview and a standardized examination,
including measurement of the standing waist circumfer-
ence (in the horizontal plane at the level just above the
right iliac crest, at minimal respiration) [24,25]. Serum
TGs were measured enzymatically after hydrolysis to glyc-
erol (Hitachi 704 Analyzer; Boehringer Mannheim, Indi-
anapolis, Indiana); the coefficient of variation was 3–5
percent over the study and across the clinical range. Addi-
tional details of all laboratory procedures are available
elsewhere [26]. Calculations of low-density lipoprotein
(LDL) cholesterol concentration were limited to partici-
pants with TG concentrations below 4.5 mmol/L (a
requirement of the Friedewald equation [27]) who had
fasted at least nine hours.
Sampling weights from NHANES III were used with the
software programs SAS, SAS/Graph (Release 8.2, SAS
Institute, Cary, NC), and SUDAAN (Release 8.0, Research
Triangle Institute, Research Triangle, NC), to estimate the
sizes of the represented adult populations, to describe the
distributions in the population of risk factors associated
with LAP and BMI, and to perform analyses using multi-
variable linear regression. The analyses thus incorporated
sampling weights that accounted for unequal selection
probabilities (clustered design, planned oversampling,
and differential nonresponse) [28]. Based on the sam-
pling weights assigned, the analytic cohort represented an
estimated total of 100,048,439 US adults aged 18+ years,
50.5 percent (SE 0.7) of them women, with a distribution
of race-ethnicity that was 76.0 (1.5) percent non-Hispanic
white, 10.5 (0.6) percent non-Hispanic black, 5.3 (0.5)
percent Mexican American, and 8.1 (1.1) percent other.BMC Cardiovascular Disorders 2005, 5:26 http://www.biomedcentral.com/1471-2261/5/26
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Age-specific distributions by waist circumference and fasting triglyceride concentrations, from NHANES III Figure 1
Age-specific distributions by waist circumference and fasting triglyceride concentrations, from NHANES III. 
For consecutive age groups the population density is increasingly displaced away from the hypothetical origin points of zero 
lipid accumulation (solid triangles). For clarity of presentation, the bubble plots omit the extreme outlying values for WC and 
TG.BMC Cardiovascular Disorders 2005, 5:26 http://www.biomedcentral.com/1471-2261/5/26
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Sex-specific bubble plots of population density by the val-
ues for WC (to the nearest cm) and TG concentration (to
the nearest 0.1 mmol/L) were prepared to represent US
adults in three age ranges (figure 1). The area of each bub-
ble on these plots is proportional to the estimated number
of men or women represented by those intersections. A
sex-specific hypothetical minimum value for WC (that is,
the waist size that theoretically contained only abdominal
muscle, viscera, and vertebral bone) was estimated by cal-
culating the mean minus two standard deviations of the
log-transformed WC value among the estimated 15.00
million persons aged 18–24 years. These estimated mini-
mum WC values (65 cm for men and 58 cm for women)
were very similar to minimum values reported in a survey
of 18 year-old Canadians in 1981 [29].
The minimum WC values were used to define sex-specific
origin points (near the left-lower corner of each panel in
figure 1) that represented a hypothetical state in which TG
concentrations were arbitrarily set to zero and the waist
size (greater for men than women) comprised primarily
lean truncal tissue. A comparison of sex-specific bubble
plots by age group confirmed that increasing age was
accompanied by a shift of the population density upward
(increasing waist size) and to the right (increasing circu-
lating TG). Consistent with this empirical observation, the
LAP was defined to describe the extent to which an indi-
vidual had travelled the route – in theory – of both
increasing waist and increasing TG:
LAP for men = (WC [cm] - 65) × (TG concentration
[mmol/L])
LAP for women = (WC [cm] - 58) × (TG concentration
[mmol/L])
In order to avoid having nonpositive values for LAP, any
waist values for men that were 65 cm or less (five men in
the NHANES III sample, all aged 18–22 years) were
revised upward to 66.0 cm. No women in the entire
NHANES III sample had a waist circumference less than
58.4 cm.
Comparing LAP with BMI
Assessment of discordant subpopulations
Starting with the estimated full population, two subpopu-
lations were identified for which the quartile classifica-
tions for LAP and BMI were discordant (table 1). The
subpopulation whose ordinal LAP quartile was greater
than their ordinal BMI quartile (i.e., those located below
the bolded diagonal cells in table 1) was compared with
the subpopulation whose ordinal LAP quartile was less
than their ordinal BMI quartile (i.e., those located above
the bolded diagonal cells). An estimated 48.91 million
individuals (47.7 percent of the men, 50.1 percent of the
women) were located in discordant quartiles. To calculate
the effect of these discordant classifications on 11 cardio-
vascular risk variables, the two discordant subpopulations
were compared in linear regression models using adjust-
ments for sex and race-ethnicity and then again with fur-
ther adjustment for age (terms for age and age2). All
comparisons are reported with two-sided p values.
Comparison of continuous linear regression models in the full 
population
Linear regression models were prepared from the entire
population (discordant and concordant) that used either
log-transformed LAP (ln LAP) or log-transformed BMI (ln
BMI) as continuous independent variables. The depend-
ent (outcome) variables were the same set of 11 cardiovas-
cular risk factors. Models were also prepared separately for
two age groups, those under age 50 years and those aged
50+ years, with adjustments for race-ethnicity and for sex
when the sexes were combined. For each outcome risk var-
iable, ln LAP and ln BMI were evaluated by comparing the
proportion of the total variation that each index could
explain, that is, R2 for the entire model minus R2 for a base
model that excluded ln LAP and ln BMI. For these contin-
uous analyses, the beta coefficients (slopes) were stand-
ardized to reflect the increment in each outcome variable
associated with an increment of one standard deviation
Table 1: Distribution of US adults by population quartiles of lipid accumulation product and body mass index. Table shows number of 
survey participants and corresponding population estimates (millions, in parentheses). Participants identified in the bold-print cells are 
concordant for their quartile assignment both to LAP and BMI.
Quartiles of lipid accumulation product (LAP)
43 21 T o t a l
Quartiles of body mass index (BMI) 4 1543 (15.45) 809 (7.30) 248 (2.26) 21 (0.17) 2621 (25.19)
3 686 (6.93) 983 (9.66) 724 (7.28) 164 (1.42) 2557 (25.30)
2 191 (2.23) 531 (6.08) 742 (9.53) 521 (6.93) 1985 (24.77)
1 34 (0.39) 176 (1.95) 494 (5.97) 1313 (16.49) 2017 (24.79)
Total 2454 (25.00) 2499 (24.99) 2208 (25.03) 2019 (25.02) 9180 (100.05)BMC Cardiovascular Disorders 2005, 5:26 http://www.biomedcentral.com/1471-2261/5/26
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from the mean (calculated for each sex and age group
[18–49 years or 50+ years]) of either ln LAP or ln BMI.
Results
Distributions of LAP and BMI
The population-based distributions of LAP and BMI were
skewed to the right (table 2), but with logarithmic trans-
formation both indices approached a normal distribution
within each age group. Mean and median values rose con-
sistently with age for both LAP and BMI. However, for LAP
(more than for BMI) the values for men rose more rapidly
before age 50 years. Above that age the sex differences
were attenuated. Within the middle age range (25–49
years) the upper quartile of men's LAP was greater than
the women's upper quartile, but for the upper quartile of
BMI the sex contrast went in the opposite direction.
Applied to the entire adult age range, the male and female
quartile cutpoints for LAP were similar, although the
men's values were slightly higher than the women's (fig-
ure 2). For BMI, the quartile cutpoints were higher for
men than women at the 25th and 50th percentiles (23.3
and 25.7 vs. 21.7 and 24.8 kg/m2), but at the 75th percen-
tile the BMI cutpoint was lower for men than women
(28.9 vs. 29.6 kg/m2).
The linear correlation between LAP and BMI for the adult
population was modest (r = 0.58) and somewhat stronger
when both indices were log-transformed (r = 0.71).
Comparisons of LAP with BMI regarding cardiovascular 
risk variables
Analyses restricted to discordant subpopulations
Compared to the subpopulation with ordinal BMI quar-
tile > ordinal LAP quartile, the subpopulation with ordi-
nal LAP quartile > ordinal BMI quartile was older [50.5
(SE 0.7) years vs. 38.5 (0.6) years], had more non-His-
panic whites [82.2 (1.8) vs. 69.4 (2.0) percent], and fewer
non-Hispanic blacks [5.2 (0.5) vs. 17.5 (1.3) percent] and
Mexican Americans [4.4 (0.5) vs. 5.9 (0.6) percent]. In
regression models adjusted for sex and race-ethnicity
(table 3), they had more adverse levels for all 11 of the
evaluated cardiovascular risk factors (p < 0.002). These
included the two factors for which mean values are
inversely associated with risk – concentration of high-den-
sity-lipoprotein (HDL) cholesterol and ratio of low-den-
sity-lipoprotein (LDL) cholesterol to apolipoprotein B
(i.e., smaller size of LDL particles [30]). With additional
adjustment for age, the relatively adverse status of higher
LAP was no longer seen for systolic and diastolic blood
pressure (p > 0.1), but it remained (p < 0.0005) for all
seven lipid variables, uric acid concentration, and heart
rate (table 3, right columns). The exclusion of persons
who reported that they were taking medicine prescribed
for high blood pressure (prevalence 11.3 percent) or to
lower their cholesterol (prevalence 2.8 percent) did not
alter any of these observed relationships (data not
shown).
Analyses of continuous linear regression models in the full population
Ln LAP consistently explained a greater portion of the var-
iation of the outcome variables than did ln BMI for all
seven lipid outcome variables, uric acid concentration,
Table 2: Population estimates of lipid accumulation product and body mass index by sex and age group. Estimates derived for US 
adults from NHANES III, 1988–1994.
Lipid accumulation product (LAP) 
cm·mmol/L
Body mass index (BMI) kg/m2
P e r c e n t i l e P e r c e n t i l e
Sex & age Survey 
sample (N)
Geometric 
mean
25th 50th 75th Geometric 
mean
25th 50th 75th
Men
18–24 years 685 16.2 9.2 15.5 27.6 23.6 21.1 23.1 25.7
25–49 years 1982 35.0 20.1 35.5 63.2 26.4 23.7 25.9 29.0
50+ years 1780 52.4 33.3 53.4 85.6 26.9 24.3 26.8 29.9
Women
18–24 years 715 16.6 9.4 16.0 27.6 23.1 20.0 22.4 25.6
25–49 years 2216 25.7 13.6 24.6 47.7 25.4 21.5 24.6 29.5
50+ years 1802 50.2 29.6 51.7 84.5 26.9 23.1 26.4 30.7
All
18–24 years 1400 16.4 9.2 15.7 27.6 23.4 20.6 22.8 25.6
25–49 years 4198 30.1 16.4 29.7 57.3 25.9 22.5 25.3 29.1
50+ years 3582 51.2 31.1 52.6 85.3 26.9 23.8 26.6 30.3BMC Cardiovascular Disorders 2005, 5:26 http://www.biomedcentral.com/1471-2261/5/26
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and heart rate (figure 3). For most of these variables the
proportion of total variance explained (R2) by ln LAP was
about twice that of ln BMI. For the remaining two
variables, systolic and diastolic blood pressure, the con-
trasts in portion of explained variation were small but
consistent between the sexes. In the population under age
50 years, ln BMI was the better predictor of systolic blood
pressure, but ln LAP was better for diastolic pressure. In
the population aged 50+ years, ln LAP was the stronger
predictor of systolic blood pressure.
A similar pattern was seen in a comparison of the stand-
ardized beta coefficients applied to the entire adult age
range (data not shown). The beta coefficient (slope) of ln
LAP was consistently more adverse (p < 0.01) than that of
ln BMI for nine of the cardiovascular risk variables, but
not for systolic and diastolic blood pressures (p > 0.2).
When these comparative models were stratified by the two
age groups the relatively greater slope of ln LAP was pre-
served among the nine variables for both age groups
(table 4). Again, the exclusion of self-reported medication
users did not alter these relationships (data not shown).
When the separate component measures that contribute
to LAP (i.e., WC and TG concentration) were log-trans-
formed and entered individually into predictive models,
their standardized beta coefficients generally showed
lesser or equivalent (p > 0.05) slopes compared to the
slopes for LAP. The only exception was for the estimation
of the ratio LDL cholesterol/Apo B among adults 18–49
years old. In this group the slope for ln TG alone [-0.160
(0.019)] was more steeply negative (p = 0.02) than the
slope for ln LAP [-0.090 (0.017)].
Discussion
The index described in this paper – the lipid accumulation
product (LAP) – was developed in an effort to reflect the
combined anatomic and physiologic changes associated
with lipid overaccumulation in adults. Compared with
BMI, LAP exhibited better correlations with lipid risk var-
iables, uric acid concentration, and heart rate, but its cor-
relation with blood pressure was roughly equivalent.
It is reasonable to speculate that the two LAP components
– that is, enlarged abdominal fat depots and increased TG
concentration – are each an indication that available lipid
fuels have exceeded the individual's capacity to buffer and
safely store this major form of acquired energy. Prior to 50
years old, the LAP appears to rise more slowly with age for
women compared to men (Table 2). The women's relative
delay of lipid overaccumulation is consistent with their
greater amount of lower-body adipose tissue that confers
increased buffering and storage capacity.
Whether an individual's excess lipid fuel appears eventu-
ally as an enlarged abdomen or as elevated circulating TG
could be dictated in part by genes or by features of the
individual's environmental circumstances. A special case,
by way of an extreme example, might be the rare individ-
ual who is genetically disposed to extremely high TG con-
centrations (chylomicronemia). For the purpose of risk
assessment in the general adult population, however, the
alternative manifestations of lipid overaccumulation
could be similarly informative. Regardless if the overaccu-
mulation is marked by waist size, by TG concentration, or
by both, the calculated value of LAP will be increased. In
parallel with the LAP increments, excess lipid material will
increasingly be deposited in nonadipose, "ectopic" tissues
(e.g., liver, skeletal muscle, heart, blood vessels, kidneys,
Lines of equivalent percentile value for the lipid accumulation  product (LAP) among US adults Figure 2
Lines of equivalent percentile value for the lipid accu-
mulation product (LAP) among US adults. Population 
estimates from NHANES III (USA, 1988–1994) are shown 
separately for men (top panel) and women (bottom panel). 
The presented iso-LAP values (95th through 25th percen-
tiles) are 144.7, 112.0, 66.1, 37.4, and 19.1 cm·mmol/L for 
men and 135.6, 103.5, 60.4, 30.3, and 15.6 cm·mmol/L for 
women.
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and pancreas) where it may adversely modify cellular
metabolism, accelerate apoptosis (cell death), and inter-
fere with cardiovascular control [10,11,31].
Ectopic lipid deposition is difficult to quantify directly,
but an increased LAP value may indicate that various
tissues or organs have become more vulnerable to injury
from lipid overaccumulation. Lipoprotein particles with
small diameters are more associated with disease risk than
those with large diameters [32,33], and lipoprotein parti-
cle diameter is inversely associated with abdominal size
[34]. Thus, LAP may effectively express disease risk
through the hyperbolic relationship between LAP and its
two component variables (Figure 2). The presence of an
enlarged waist (implying a small lipoprotein particle size)
allows the LAP value to increase rapidly with each unit
increase in TG concentration. By contrast, the presence of
a small waist (implying a large lipoprotein particle size)
allows the LAP value to increase slowly with each unit
increase in TG concentration. Although the NHANES III
data set contains no direct measurement of particle sizes,
our indirect estimate of LDL particle size (LDL
cholesterol/ApoB) confirms that a small LDL particle size
is better correlated with LAP than with BMI (Figure 3 and
Table 4).
In contrast to an elevation in LAP value, an elevated BMI
value (i.e., relative weight) is less specific in its anatomic
or physiologic implications. Increased weight might rep-
resent enhancement of lean tissues, enlargement of the
protective, subcutaneous adipose depots in the lower
extremities [5,35-37], or systemic overload of fluid –
changes that could be either salutary or simply secondary
consequences of other disease processes. The commonly
observed association of fluid overload with hypertension
may explain the instances in which this study found
blood pressure to be marginally better correlated with
BMI than with LAP (Table 4 and Figure 3).
In order for LAP to gain a useful role in clinical medicine
or epidemiology, at least three major questions remain to
be addressed:
1. Is LAP strongly predictive of major disease outcomes? This
preliminary analysis examined only intermediary out-
comes (risk factors), and its data are entirely cross-sec-
tional. However, a 20-year followup study of Swedish
women reported that abdominal adiposity and elevated
TG concentration were associated with increased risks of
death from myocardial infarction and all causes, but that
elevated BMI and cholesterol concentration were much
weaker predictors [38]. In another prospective study from
Scandinavia, post-menopausal women followed for 8.5
years demonstrated that the baseline combination of
enlarged waist with elevated triglycerides – a dichoto-
mous marker – was a very strong predictor of all-cause and
cardiovascular mortality as well as the annual progression
rate of aortic calcification [39]. More data collected pro-
spectively in a variety of populations, including men,
would help confirm that LAP – a continuous marker – has
advantages over other simple indices for predicting the
incidence of major diseases and mortality.
Table 3: Mean levels of cardiovascular risk variables among the subpopulations discordant for quartiles of LAP and BMI. Estimates 
derived for US adults from NHANES III, 1988–1994.
Mean (SE) adjusted for sex and 
race-ethnicity
Mean (SE) adjusted for sex, race-
ethnicity, and age
Dependent variable, units Discordant 
survey sample 
(N)
LAP quartile > 
BMI quartile
BMI quartile > 
LAP quartile
P value LAP quartile > 
BMI quartile
BMI quartile > 
LAP quartile
P value
Total cholesterol, mmol/L 4598 5.62 (0.04) 4.89 (0.04) <0.0001 5.50 (0.04) 5.00 (0.04) <0.0001
HDL cholesterol, mmol/L 4578 1.24 (0.01) 1.37 (0.01) <0.0001 1.22 (0.01) 1.39 (0.01) <0.0001
LDL cholesterol, mmol/L 3333 3.50 (0.04) 3.11 (0.05) <0.0001 3.40 (0.04) 3.20 (0.05) 0.0003
Total cholesterol / HDL cholest. 4577 4.93 (0.06) 3.78 (0.05) <0.0001 4.88 (0.06) 3.82 (0.05) <0.0001
Apolipoprotein B, g/L 2245* 1.13 (0.01) 0.94 (0.01) <0.0001 1.10 (0.01) 0.97 (0.01) <0.0001
ApoB/ApoA1 2230* 0.809 (0.012) 0.681 (0.010) <0.0001 0.799 (0.013) 0.690 (0.010) <0.0001
LDL cholesterol /ApoB, mmol/g 1614* 3.06 (0.04) 3.26 (0.03) 0.0007 3.03 (0.04) 3.29 (0.03) <0.0001
Uric acid, mmol/L 4533 327 (2) 311 (3) <0.0001 325 (2) 313 (3) 0.0004
Systolic blood pressure, mmHg 4595 124.9 (0.7) 118.3 (0.4) <0.0001 121.3 (0.6) 121.6 (0.4) 0.62
Diastolic blood pressure, mmHg 4595 74.5 (0.3) 73.0 (0.3) 0.0018 74.1 (0.3) 73.4 (0.3) 0.14
Heart rate, bpm 4494 75.0 (0.5) 72.4 (0.6) 0.0005 75.1 (0.5) 72.3 (0.6) 0.0001
* Lipoprotein data obtained only during phase 1 of NHANES III.BMC Cardiovascular Disorders 2005, 5:26 http://www.biomedcentral.com/1471-2261/5/26
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2. Is it useful to monitor LAP values as an indicator of interven-
tion effectiveness? A recent report of intentional weight loss
among overweight and obese Japanese women found that
their exercise regimen and low-calorie diet were rewarded
with a 37 percent reduction in TG concentration and a 27
percent reduction in truncal fat but only a 2 percent reduc-
tion in leg fat and a 12 percent reduction in BMI [40]. The
authors also reported a direct correlation between changes
in truncal fat and changes in fasting TG concentration or
the number of heart disease risk factors, but that the
changes in leg fat were inversely  correlated with the
changes in TG concentration or the number of heart dis-
ease risk factors. In another study, Italian men and women
with diabetes were followed for two years after
randomization to a physical activity counselling interven-
tion [41]. Across six levels of aerobic energy expenditure,
those who exercised more experienced significant reduc-
tions (p < 0.001) in waist circumference and circulating
TG, but no reductions (p > 0.25) in either weight or BMI.
Thus, the participants in both of these studies would have
achieved a substantial reduction in LAP in association
with improved cardiovascular risk factors, but their reduc-
tion in BMI was modest and less clearly associated with
cardiovascular benefit. These observations from Asia and
Europe demonstrate a potential advantage to using LAP as
an intermediary variable by which to assess interventions
against obesity-related risk.
3. Is LAP a practical index for adoption by clinicians or epide-
miologists? Standardized waist measurements are highly
reproducible [42], and they are arguably simpler and less
expensive to obtain than well standardized weights and
heights. The requirement of a venipuncture, however,
could be a major obstacle for many potential participants
or patients. The need for the fasting state could also repre-
sent a major inconvenience, although many persons
accept the fasting condition when necessary for assess-
ment of their glucose or lipid status. Of special impor-
tance in less developed economies, the laboratory cost of
a single assay for TGs would be low compared with the
costs of multiple assays for lipoproteins and an extensive
biochemical panel.
Conclusion
The cross-sectional associations with LAP demonstrated
in this paper should be seen primarily as a demonstration
of how the concept of lipid overaccumulation may be
expressed in an adult population. The utility of LAP for
research or as a practical tool for use in the community
will depend on the degree to which LAP can be demon-
strated to enhance prediction of disease incidence. Pro-
spective data sets that include baseline information on
WC and fasting TG concentration would be well suited to
evaluate LAP as a predictor of cardiovascular outcomes
and mortality.
Abbreviations
ApoA1, apolipoprotein A1
ApoB, apolipoprotein B
BMI, body mass index
HDL, high-density lipoprotein
LAP, lipid accumulation product
Proportion of total population variation (R2) in risk variables  explained by Ln LAP and Ln BMI Figure 3
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